JP2016540505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540505A5 JP2016540505A5 JP2016533143A JP2016533143A JP2016540505A5 JP 2016540505 A5 JP2016540505 A5 JP 2016540505A5 JP 2016533143 A JP2016533143 A JP 2016533143A JP 2016533143 A JP2016533143 A JP 2016533143A JP 2016540505 A5 JP2016540505 A5 JP 2016540505A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- cancer
- replication competent
- competent oncolytic
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907860P | 2013-11-22 | 2013-11-22 | |
| US61/907,860 | 2013-11-22 | ||
| PCT/US2014/066920 WO2015077624A1 (en) | 2013-11-22 | 2014-11-21 | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238013A Division JP2020048582A (ja) | 2013-11-22 | 2019-12-27 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016540505A JP2016540505A (ja) | 2016-12-28 |
| JP2016540505A5 true JP2016540505A5 (https=) | 2017-12-28 |
Family
ID=53180213
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533143A Withdrawn JP2016540505A (ja) | 2013-11-22 | 2014-11-21 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| JP2019238013A Pending JP2020048582A (ja) | 2013-11-22 | 2019-12-27 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| JP2021097883A Pending JP2021137029A (ja) | 2013-11-22 | 2021-06-11 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238013A Pending JP2020048582A (ja) | 2013-11-22 | 2019-12-27 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| JP2021097883A Pending JP2021137029A (ja) | 2013-11-22 | 2021-06-11 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20160289645A1 (https=) |
| EP (2) | EP3071697B1 (https=) |
| JP (3) | JP2016540505A (https=) |
| KR (1) | KR20160137946A (https=) |
| CN (2) | CN114317461A (https=) |
| AU (1) | AU2014352749A1 (https=) |
| CA (1) | CA2931322A1 (https=) |
| DK (1) | DK3071697T3 (https=) |
| ES (1) | ES2765489T3 (https=) |
| SG (1) | SG10201907841UA (https=) |
| WO (1) | WO2015077624A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120087933A1 (en) | 2010-10-08 | 2012-04-12 | Samson Tom | Enhanced msc preparations |
| AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| AU2014338864C1 (en) | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| KR20250081944A (ko) | 2014-09-24 | 2025-06-05 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| BR112017016681A2 (pt) * | 2015-02-06 | 2018-04-10 | Heat Biologics Inc | vetor de coexpressão de vacina e moléculas coestimulatórias |
| PE20180241A1 (es) | 2015-04-30 | 2018-01-31 | Psioxus Therapeutics Ltd | Adenovirus oncolitico que codifica una proteina b7 |
| CA2984794A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| JP6954648B2 (ja) * | 2015-10-19 | 2021-10-27 | シージー オンコロジー， インコーポレイテッド | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
| EA201891022A1 (ru) | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| EP3778881A1 (en) | 2016-01-08 | 2021-02-17 | Replimune Limited | Modified oncolytic virus |
| EP4155411A1 (en) | 2016-02-23 | 2023-03-29 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| PL3426271T3 (pl) | 2016-03-10 | 2025-11-24 | Cg Oncology, Inc. | Sposoby leczenia guzów litych terapią skojarzoną |
| EP3463405A4 (en) * | 2016-05-27 | 2020-02-26 | DNAtrix, Inc. | Adenovirus and immunomodulator combination therapy |
| CN119614520A (zh) | 2016-08-29 | 2025-03-14 | 阿卡米斯生物公司 | 携带双特异性t细胞衔接器的腺病毒 |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| SI3293201T1 (sl) * | 2016-09-12 | 2021-03-31 | Targovax Oy | Kombinacija zaviralcev adenovirusa in zaviralcev kontrolnih točk za zdravljenje raka |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| WO2018111902A1 (en) * | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| US11298420B2 (en) * | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| EP3565578A1 (en) | 2016-12-21 | 2019-11-13 | Memgen LLC | Armed replication-competent oncolytic adenoviruses |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CN108338994A (zh) | 2017-01-25 | 2018-07-31 | 杭州康万达医药科技有限公司 | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 |
| CA3058938A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
| AU2018251987B2 (en) | 2017-04-14 | 2024-11-28 | Cg Oncology, Inc. | Methods of treating bladder cancer |
| CN109276580B (zh) | 2017-07-21 | 2021-08-24 | 厦门大学 | 一种用于治疗肿瘤的病毒 |
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| CN119033819A (zh) | 2017-11-22 | 2024-11-29 | 迈索布拉斯特国际有限公司 | 细胞组合物及治疗方法 |
| CN107952069A (zh) * | 2017-11-24 | 2018-04-24 | 长春百克生物科技股份公司 | 重组疫苗及其应用 |
| CN109985241B (zh) * | 2017-12-29 | 2024-10-18 | 广州威溶特医药科技有限公司 | Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
| EP3768698B1 (en) | 2018-03-19 | 2025-02-12 | MultiVir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| US12295976B2 (en) | 2018-03-28 | 2025-05-13 | Epicentrx, Inc. | Personalized cancer vaccines |
| MX2020010499A (es) | 2018-04-09 | 2020-10-28 | Salk Inst For Biological Studi | Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion. |
| WO2020047345A1 (en) | 2018-08-31 | 2020-03-05 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| BR112021004692A2 (pt) * | 2018-09-15 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | poxvírus recombinantes para imunoterapia de câncer |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3927833A4 (en) * | 2019-02-21 | 2022-11-30 | Unleash Immuno Oncolytics, Inc. | ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE |
| BR112022001912A2 (pt) | 2019-08-05 | 2022-04-19 | Mesoblast Int Sarl | Composições celulares compreendendo vetores virais e métodos de tratamento |
| KR20220115569A (ko) | 2019-11-18 | 2022-08-17 | 얀센 바이오테크 인코포레이티드 | 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도 |
| CN110859968A (zh) * | 2019-11-21 | 2020-03-06 | 四川安可康生物医药有限公司 | 激活对肿瘤的系统免疫反应的基因生物药物 |
| CN115243714A (zh) * | 2020-03-06 | 2022-10-25 | 匹兹堡大学联邦系统高等教育 | 用于治疗癌症的表达irf调节剂的溶瘤病毒 |
| WO2021252496A1 (en) * | 2020-06-10 | 2021-12-16 | Richard Lowenthal | Engineered adenovirus vectors and uses thereof |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022034506A1 (en) | 2020-08-10 | 2022-02-17 | Mesoblast International Sárl | Cellular compositions and methods of treatment |
| JP7614980B2 (ja) | 2021-08-25 | 2025-01-16 | 三菱重工航空エンジン株式会社 | 燃焼器パネル、及びガスタービン用燃焼器 |
| WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| DE69628744D1 (de) | 1995-04-17 | 2003-07-24 | Univ Texas System Austin Board | Adenovirus helfervirus system |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6682928B2 (en) * | 1997-12-02 | 2004-01-27 | Medarex, Inc. | Cells expressing anti-Fc receptor binding components |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| US7368527B2 (en) * | 1999-03-12 | 2008-05-06 | Human Genome Sciences, Inc. | HADDE71 polypeptides |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| WO2003064666A1 (en) * | 2002-02-01 | 2003-08-07 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with pods |
| CA2489004C (en) | 2002-06-13 | 2013-01-08 | Crucell Holland B.V. | Agonistic binding molecules to the human ox40 receptor |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| CN102558352A (zh) | 2003-06-27 | 2012-07-11 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| CN101166539B (zh) * | 2005-02-08 | 2012-01-04 | 得克萨斯大学体系董事会 | 用于治疗癌症的涉及mda-7的组合物和方法 |
| DK2650020T3 (en) | 2005-05-06 | 2017-01-16 | Providence Health & Services - Oregon | Trimeric OX40 immunoglobulin fusion protein and methods for applications. |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| ES2304281B1 (es) * | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| CN103536915A (zh) | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| CN102575227A (zh) * | 2008-10-08 | 2012-07-11 | 英特瑞克斯顿股份有限公司 | 表达多种免疫调节剂的工程改造细胞及其应用 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| SMT201700185T1 (it) * | 2010-08-23 | 2017-05-08 | Univ Texas | Anticorpi anti-ox40 e metodi di uso degli stessi |
| RU2013118724A (ru) * | 2010-09-24 | 2014-10-27 | Онкос Терапьютикс Ой | Онколитические аденовирусные векторы и связанные с ними способы и применения |
| EP3187603B1 (en) * | 2011-02-17 | 2024-06-26 | Arconic Technologies LLC | 2xxx series aluminum lithium alloys |
| CN114262690A (zh) * | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| DK2806883T3 (da) * | 2012-01-25 | 2019-07-22 | Dnatrix Inc | Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation |
| CN104271748B9 (zh) * | 2012-02-02 | 2019-05-24 | 得克萨斯州大学系统董事会 | 表达异源肿瘤相关抗原的腺病毒 |
-
2014
- 2014-11-21 CA CA2931322A patent/CA2931322A1/en not_active Abandoned
- 2014-11-21 ES ES14864921T patent/ES2765489T3/es active Active
- 2014-11-21 KR KR1020167016399A patent/KR20160137946A/ko not_active Ceased
- 2014-11-21 AU AU2014352749A patent/AU2014352749A1/en not_active Abandoned
- 2014-11-21 JP JP2016533143A patent/JP2016540505A/ja not_active Withdrawn
- 2014-11-21 EP EP14864921.3A patent/EP3071697B1/en active Active
- 2014-11-21 SG SG10201907841U patent/SG10201907841UA/en unknown
- 2014-11-21 EP EP19203386.8A patent/EP3653714A1/en not_active Withdrawn
- 2014-11-21 CN CN202111419932.6A patent/CN114317461A/zh active Pending
- 2014-11-21 CN CN201480073813.1A patent/CN106029889A/zh active Pending
- 2014-11-21 WO PCT/US2014/066920 patent/WO2015077624A1/en not_active Ceased
- 2014-11-21 DK DK14864921.3T patent/DK3071697T3/da active
- 2014-11-21 US US15/038,446 patent/US20160289645A1/en not_active Abandoned
-
2018
- 2018-06-27 US US16/020,738 patent/US20190093085A1/en not_active Abandoned
-
2019
- 2019-12-27 JP JP2019238013A patent/JP2020048582A/ja active Pending
-
2021
- 2021-06-11 US US17/304,006 patent/US20210301264A1/en not_active Abandoned
- 2021-06-11 JP JP2021097883A patent/JP2021137029A/ja active Pending
-
2024
- 2024-10-10 US US18/912,157 patent/US20250171745A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016540505A5 (https=) | ||
| ES2765489T3 (es) | Adenovirus que expresa agonista(s) del receptor estimulante de células inmunitarias | |
| ES2971065T3 (es) | Terapia de combinación de virus vaccinia oncolítica y un inhibidor de punto de control | |
| Lemay et al. | Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine | |
| JP2015506704A5 (https=) | ||
| Koske et al. | Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment | |
| AU2017207532A1 (en) | Oncolytic virus and checkpoint inhibitor combination therapy | |
| EP3400293A1 (en) | Modified oncolytic virus | |
| CN117731763A (zh) | 过继细胞转移与溶瘤病毒组合疗法 | |
| BR112021001117A2 (pt) | células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas | |
| WO2020025642A1 (en) | Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer | |
| Pol et al. | Oncolytic viruses: a step into cancer immunotherapy | |
| US20220211814A1 (en) | Il-36 cytokine expressing oncolytic viruses for treating cancer | |
| US12611444B2 (en) | IL-36 cytokine expressing oncolytic viruses for treating cancer | |
| US20240325473A1 (en) | Cancer Treatments | |
| CA3060516C (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| Olsen et al. | Neuro-Oncology Advances | |
| Witt | Cripto-1: potential target for cancer immunotherapy?! | |
| HK40097178A (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| HK40030022A (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| Rajani et al. | Viral platforms for expression of tumor antigens in cancer immunotherapy | |
| HK1230236A1 (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| Lohr et al. | Experimental treatment of pancreatic cancer | |
| HK40025045B (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| HK40025045A (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |